Compare H2O America (HTO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs TG Therapeutics Inc — how do they compare? H2O America trades at $58.48 (market cap $2.43B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 3.4× H2O America's market cap, and H2O America pays a 3.03% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 40 Days and TG Therapeutics Inc for 16 Days on average.
| HTO | TGTX | |
|---|---|---|
Market Cap | $2.43B | $8.16B |
Volume | 593,883 | 1,735,121 |
Sector | Utilities | Health |
52-Week High | $65.43 | $59.06 |
52-Week Low | $44.44 | $26.94 |
Typical Hold Time | 40 Days | 16 Days |
Enterprise Value | $4.22B | $8.37B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.48, up 0.86% with a bearish technical signal despite bullish oscillators. The company shows stable fundamentals with 12.91% net margin and consistent earnings beats in recent quarters. Recent Texas acquisitions signal growth strategy, though cash flow trends show heavy investment activity. Analyst consensus remains strongly bullish with 83% buy ratings and $66.50 price target.
HTO presents a compelling value opportunity with strong analyst support and strategic expansion, though execution risks from recent acquisitions and bearish technical indicators warrant caution. The stock's current discount to consensus target offers potential upside for patient investors willing to navigate near-term volatility.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
